Trials / Terminated
TerminatedNCT04890353
Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimethyl fumarate | Dimethyl fumarate 240mg orally twice daily for 3 consecutive days |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2023-02-08
- Completion
- 2023-02-28
- First posted
- 2021-05-18
- Last updated
- 2023-10-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04890353. Inclusion in this directory is not an endorsement.